Full text
PDFPage 375
. 1993 Feb;37(2):375.
Outbreak of Ceftazidime Resistance Due to a Novel Extended-Spectrum β-Lactamase in Isolates from Cancer Patients
Louie Naumovski
1, John P Quinn
1, Deborah Miyashiro
1, Marlynn Patel
1, Karen Bush
1, Susan B Singer
1, Donna Graves
1, Tim Palzkill
1, Ann M Arvin
1
Louie Naumovski
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Louie Naumovski
John P Quinn
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by John P Quinn
Deborah Miyashiro
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Deborah Miyashiro
Marlynn Patel
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Marlynn Patel
Karen Bush
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Karen Bush
Susan B Singer
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Susan B Singer
Donna Graves
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Donna Graves
Tim Palzkill
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Tim Palzkill
Ann M Arvin
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Find articles by Ann M Arvin
1Department of Pediatrics, Divisions of Hematology/Oncology and Infectious Diseases, Stanford University School of Medicine, and Clinical Microbiology Laboratory, The Children's Hospital at Stanford, Stanford, California 94305; Department of Medicine, Division of Infectious Diseases, Humana Hospital-Michael Reese, Chicago, Illinois 60616; Medical Research Division, American Cyanamid, Pearl River, New York 10965; Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey 08540; and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030
PMCID: PMC187674
This corrects the article "Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients." in volume 36 on page 1993.